Skip to main content

Table 3 Base case results of screening strategies forming the cost-effectiveness frontier (per person)

From: Lung cancer screening by low-dose computed tomography: a cost-effectiveness analysis of alternative programmes in the UK using a newly developed natural history-based economic model

Strategy Change in 5-year lung cancer survival Costs QALYs ICER (versus current/no screening) ICER (versus previous)
No screening   £1103 8.50215   
S-60-75-3%a + 16.1% £1126 8.50297 £28,169 £28,169
S-55-75-3% + 16.4% £1129 8.50306 £28,784 £35,453
S-55-80-3% + 16.1% £1135 8.50319 £30,821 £44,087
T-55-80-3% + 21.0% £1151 8.50337 £40,034 £95,292
  1. aIn a fully incremental analysis, only S-60-75-3% would be cost-effective at a threshold of £30,000 per QALY gained. ICER incremental cost-effectiveness ratio, QALY quality-adjusted life year, S single one-off screen design, T triple-screen design. Strategy nomenclature: X-XX-XX-X% = screening programme design type-minimum entry age-maximum entry age-minimum lung cancer risk threshold